Although cisplatin has been used extensively for the treatment of solid tumors, the best administration schedule has not been decided yet. The majority of clinical trials employ the intermittent administration using 80-100 mg/m 2 of cisplatin every 3-4 weeks. The pharmacokinetics [PK] of cisplatin are complicated. It is demonstrated that the analysis of PK for free platinum is appropriate to predict the pharrnacodynamic[PD] effect of the drug. Cisplatin is considered to be an AUC dependent drug, which means that the administration schedule does not influence the PD effect. However the detailed PK-PD analysis has not been done because physicians decide the administration schedule independently based on their clinical experiences or on the clinical protocol. In addition the effective dose to influence PD differs from patient to patient and cisplatin shows consistent antitumor effect even with different administration schedules.
Since Scanlon reported that cisplatin and 5-FU could show synergistic effect, many trials have been carried out to demonstrate it clinically(l). The mechanisms of the synergism could be explained in two different ways. According to Scanlon's data, cisplatin inhibits the transportation of methionine through cell membrane. Accordingly, the production of cellular methionine from homocysteine is increased, coupled with the increased production of tetrahydrofolate[FH4] from methylene tetrahydrofolate [CH3-FH4]. This results in the accumulation of 5,IO-methylenetetrahydrofolate[5,IO-CH2-FH4], which produces tight ternary complex with thymidylate synthase and F-dUMP. This ternary complex strongly inhibits the activity of thymidylate synthase. Another explanation is the decrease in repair of cisplatin-induced damage of DNA by FUTP, which is a metabolite of 5-FU, or the decrease in the synthesis of dITP which is considered to have a role in DNA repair (2) . In addition it is reported that cisplatin resistant cell lines acquire collateral sensitivity to 5-FU. These are extremely interesting ideas to be tested clinically (3). continuous infusion[100 mg/m'', 120 h]. The highest AUC of total and free Pt and lowest Cmax of free Pt were observed in daily continuous infusion. It was concluded that daily continuous infusion of cisplatin indicated best pharmacokinetic results. The authors observed that stomatitis was more severe in the daily continuous infusion in three patients who received the daily short term infusion and daily continuous infusion schedules sequentially. However, PK/pD analysis is extremely difficult in patients receiving combination chemotherapy. In the present study the authors observed two partial responders in the single short term infusion group in spite of the lowest AUC[free Pt]. Another problem is that the higher the PK parameter the stronger the adverse effects/drug reactions as opposed to higher antitumor activity.
In Japan continuous infusion of cisplatin and 5-FU have frequently been used not only in clinical trials but also in clinical practice. Many abstracts have been submitted to Jpn Soc Clin Oncol and numerous inconclusive results have been reported every year. In the majority of the reports, oral fluorinated pyrimidines are used instead of 5-FU. This is also one of the important questions to be addressed.
As the authors suggest, it is strongly recommended to conduct randomized controlled clinical trials with appropriate numbers of patients to demonstrate the clinical advantage or disadvantage of the continuous low-dose cisplatin combined with 5-FU or oral fluorinated pyrimidines. There are no models for PK/pD analysis in two drug combination. The development of the appropriate models is essential to determine the combined antitumor effect and adverse effects/drug reactions to anticancer drugs.
